N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions.

Dept. of Physiology, University of Kentucky, Lexington, KY, USA.
International journal of sport nutrition and exercise metabolism (Impact Factor: 1.98). 04/2011; 21(2):146-54.
Source: PubMed

ABSTRACT N-acetylcysteine (NAC) is a thiol donor with antioxidant properties that has potential use as an ergogenic aid. However, NAC is associated with adverse reactions that limit its use in humans.
The authors evaluated NAC efficacy as a thiol donor before handgrip exercise, measuring changes in serum cysteine and glutathione status and recording adverse reactions in adult subjects across a range of doses.
Healthy individuals ingested NAC capsules (9 ± 2 or 18 ± 4 mg/kg) or solution (0, 35, 70, or 140 mg/kg). Venous blood samples were collected and subjects answered a questionnaire about adverse reactions.
Low doses of NAC (capsules) did not affect plasma cysteine or glutathione or cause adverse reactions. Adverse reactions to NAC solution were predominantly mild and gastrointestinal (GI). Intensity of GI reactions to 140 mg/kg NAC was significantly higher than placebo (in a.u., 0.67 ± 0.16 vs. 0.07 ± 0.04; p < .05). Plasma cysteine concentration increased with NAC dose from 9.3 ± 0.7 μM (placebo) to 65.3 ± 6.7 μM (140 mg/kg); however, there was no difference (p > .05) in plasma cysteine for 70 mg/kg vs. 140 mg/kg. Similar increases were observed for the ratio of cysteine to total cysteine, which was directly related to handgrip exercise performance. Plasma glutathione was elevated and oxidized glutathione diminished (p < .05) with NAC 140 mg/kg vs. placebo.
NAC effects on plasma thiols are maximized by oral administration of 70 mg/kg, a dose that does not cause significant adverse reactions.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial diseases are an unusually genetically and phenotypically heterogeneous group of disorders, which are extremely challenging to treat. Currently, apart from supportive therapy, there are no effective treatments for the vast majority of mitochondrial diseases. Huge scientific effort however, is continuously put into understanding the mechanisms underlying mitochondrial disease pathology and developing potential treatments. To date a variety of treatments have been evaluated by randomised clinical trials, but unfortunately none of these has delivered breakthrough results. Increased understanding of mitochondrial pathways and the development of many animal models, some of which are accurate phenocopies of human diseases, are facilitating the discovery and evaluation of novel prospective treatments. Targeting reactive oxygen species has been a treatment of interest for many years, however only in recent years has it been possible to direct antioxidant delivery specifically into the mitochondria. Increasing mitochondrial biogenesis, whether by pharmacological approaches, dietary manipulation or exercise therapy is also currently an active area of research. Modulating mitochondrial dynamics and mitophagy and the mitochondrial membrane lipid milieu have also emerged as possible treatment strategies. Recent technological advances in gene therapy, including allotopic and transkingdom gene expression and mitochondrially-targeted transcription activator-like nucleases, have led to promising results in cell and animal models of mitochondrial diseases, but most of these techniques are still far from clinical applicability.
    British Journal of Pharmacology 10/2013; DOI:10.1111/bph.12456 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the effects of N-acetylcysteine (NAC) on metabolism during fixed work rate high-intensity interval exercise (HIIE) and self-paced 10-min time-trial (TT10) performance. Nine well-trained male cyclists (V̇O2peak, 69.4 ± 5.8 mL·kg(-1)·min(-1); peak power output (PPO), 385 ± 43 W; mean ± SD) participated in a double-blind, repeated-measures, randomised crossover trial. Two trials (NAC supplementation and placebo) were performed 7 days apart consisting of 6 × 5 min HIIE bouts at 82% PPO (316 ± 40 W) separated by 1 min at 100 W, and then after 2 min of recovery at 100 W, TT10 was performed. Expired gases, venous blood, and electromyographic (EMG) data were collected. NAC did not influence blood glutathione but decreased lipid peroxidation compared with the placebo (P < 0.05). Fat oxidation was elevated with NAC compared with the placebo during HIIE bouts 5 and 6 (9.9 ± 8.9 vs. 3.9 ± 4.8 μmol·kg(-1)·min(-1); P < 0.05), as was blood glucose throughout HIIE (4.3 ± 0.6 vs. 3.8 ± 0.6 mmol·L(-1); P < 0.05). Blood lactate was lower with NAC after TT10 (3.3 ± 1.3 vs. 4.2 ± 1.3 mmol·L(-1); P < 0.05). Median EMG frequency of the vastus lateralis was lower with NAC during HIIE (79 ± 10 vs. 85 ± 10 Hz; P < 0.05), but not TT10 (82 ± 11 Hz). Finally, NAC decreased mean power output 4.9% ± 6.6% (effect size = -0.3 ± 0.4, mean ± 90% CI) during TT10 (305 ± 57 W vs. 319 ± 45 W). These data suggest that NAC alters substrate metabolism and muscle fibre type recruitment during HIIE, which is detrimental to time-trial performance.
    Applied Physiology Nutrition and Metabolism 12/2013; 38(12):1217-27. DOI:10.1139/apnm-2012-0482 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This investigation examined the ergogenic effect of short-term oral N-acetylcysteine (NAC) supplementation and the associated changes in redox balance and inflammation during intense training. A double blind randomised placebo-controlled crossover design was used to assess 9 days of oral NAC supplementation (1200 mg/day) in 10 well-trained triathletes. For each supplement trial (NAC and placebo), baseline venous blood and urine samples were taken and a pre-supplementation cycle ergometer race simulation was performed. Following the loading period, further samples were collected pre-exercise, post-exercise, 2 h and 24 h following the post-supplementation cycle ergometer race simulation. Changes in total antioxidant capacity (TAC), ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), oxidised glutathione (GSSG), thiobarbituric acid-reactive substances (TBARS), interlukin-6 (IL-6), xanthine oxidase, hypoxanthine, monocyte chemotactic protein-1 (MCP-1), nuclear factor- κB (NF-κB) and urinary 15-isoprostane F2t concentration (F2-isoprostane) were assessed. The experimental procedure was repeated with the remaining supplement after a 3 week washout. Eight participants completed both supplementation trials. NAC improved sprint performance during the cycle ergometer race simulation (P < 0.001, η p = 0.03). Supplementation with NAC also augmented post-exercise plasma TAC (P = 0.005, η p = 0.19), reduced exercise-induced oxidative damage, [plasma TBARS (P = 0.002, η p = 0.22); urinary F2-isoprostane (P = 0.010, η p = 0.431)]; attenuated inflammation [plasma IL-6 (P = 0.002, η p = 0.22); MCP-1 (P = 0.012, η p = 0.17)] and increased post-exercise NF-κB activity (P < 0.001, η p = 0.21). Oral NAC supplementation improved cycling performance via an improved redox balance and promoted adaptive processes in well-trained athletes undergoing strenuous physical training.
    Medicine and science in sports and exercise 02/2014; DOI:10.1249/MSS.0000000000000222 · 4.46 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014